The second quarter in review

Apr - Jun 2025 (Apr - Jun 2024)

• Net sales were 13,1 (7,1) MSEK in the second quarter, an increase of 86%. In the quarter we saw sales growth in all regions.
• Operating profit in the quarter amounted to -7,6 (-12,0) MSEK (*).
• Profit for the second quarter amounted to -7,3 (-12,1) MSEK (*).
• Cash flow from operating activities was -3,1 (-10,4) MSEK. 
• The order intake for the second quarter was 27,3 (12,2) MSEK, an increase of 15,2 MSEK. The order intake was strong during the quarter, with region Europe showing a positive development.   
• Personnel costs and other external costs in total decreased during the quarter by 2,1 MSEK to 16,0 (18,1) MSEK.
• Other operating costs had a negative impact during the quarter, -0,7 (-0,4) MSEK, explained by negative currency effects from appreciation of the Swedish currency against USD and EURO.
• Earnings per share in the quarter amounted to -0,09 (-0,18) SEK - before and after dilution.
• Cash and cash equivalents at the end of the period were 27,2 (16,7) MSEK.

         (*) Q2 2024 adjusted for effects from the technology transfer agreement with Amicogen.

Message from the CEO

We ended the second quarter of 2025 with continued momentum. Order intake amounted to SEK 27.3 million - a clear increase compared to the same period last year - and we're seeing stable growth across all regions, with particularly strong development in Europe. Net sales rose by 86% to SEK 13.1 million, a sign that our offering and our focus on customer value are delivering results.

Our success is built on three cornerstones: innovative products, reliable delivery capability, and close partnerships with our customers. During the quarter, we welcomed new customers and deepened collaborations with recurring, world-leading players. Our strategy is working, and the market appreciates both the quality and flexibility of our products and services.

We continue to keep costs under control while driving growth. Personnel and other external costs decreased by SEK 2.1 million compared to the previous year, despite increased volumes. This is the result of our focused work on creating more efficient processes and strengthening our production capacity to meet rising demand. These steps are crucial for building a long-term profitable and sustainable Bio-Works.

We look forward to the second half of the year with a solid order book and a pipeline that gives reason for optimism. Our continued focus is on profitable growth, strengthening customer relationships, and developing Bio-Works into an even stronger player in the global market.

To all our employees: Your dedication and willingness to go the extra mile make all the difference. To our customers and shareholders: Thank you for your trust. Together, we are building the Bio-Works of the future - stronger, smarter, and more relevant than ever.

Lone Carlbom

CEO Bio-Works Technologies

Contacts
For more information, please visit the Bio-Works homepage at, www.bio-works.com or contact: Arne Hauge, CFO, e-mail: arne.hauge@bio-works.com, phone: +46(0)8-502 705 83.

About Bio-Works
Bio-Works enables Biotech companies to achieve their goals for purification of biomolecules. We support our customers, from laboratory research to commercial production, and together we implement efficient and robust solutions for bioprocessing. Our ambition is to be a trusted and dynamic partner in an industry characterized by growth and development.

Bio-Works' headquarters, with R&D and manufacturing, is located in Uppsala Business Park in Uppsala, Sweden. We supply products globally, through a combination of direct sales and via distributors in Europe, North America and Asia. The company is certified according to the ISO 9001:2015 quality management system. Bio-Works is listed on Spotlight Stock Market ("BIOWKS"). For more information, visit www.bio-works.com.